Article Text

Original research
External validation of three diabetes prediction scores in a Spanish cohort: does adding high risk for depression improve the validation of the FINDRISC score (FINDRISC-MOOD)?
  1. Miguel Salinero-Fort1,2,
  2. Jose M Mostaza-Prieto3,
  3. Carlos Lahoz-Rallo3,
  4. Juan Cárdenas-Valladolid4,5,
  5. Victor Iriarte-Campo1,
  6. Eva Estirado-Decabo3,
  7. Francisca Garcia-Iglesias3,
  8. Teresa Gonzalez-Alegre3,
  9. Belen Fernandez-Puntero6,
  10. Victor M Cornejo-Del Rio7,
  11. Vanesa Sanchez-Arroyo3,
  12. Concesa Sabín-Rodríguez8,
  13. Silvia López-López8,
  14. Paloma Gómez-Campelo9,
  15. Belen Taulero-Escalera10,
  16. Fernando Rodriguez-Artalejo11,12,13,
  17. Francisco Javier San Andrés-Rebollo14,
  18. Carmen De Burgos-Lunar15
  19. SPREDIA-2 Group
    1. 1 FIIBAP, Madrid, Spain
    2. 2 Frailty, patterns of multimorbidity and mortality in the community-dwelling elderly population, IdiPAZ, Madrid, Spain
    3. 3 Medicina Interna, Hospital Carlos III, Madrid, Spain
    4. 4 Gerencia Asistencial de Atención Primaria, Comunidad de Madrid Servicio Madrileno de Salud, Madrid, Spain
    5. 5 Enfermería, Universidad Alfonso X El Sabio, Villanueva de la Canada, Spain
    6. 6 Servicio de Bioquímica, Hospital Carlos III, Madrid, Spain
    7. 7 Supervisión de Enfermería, Hospital Carlos III, Madrid, Spain
    8. 8 Unidad de Día, Hospital Carlos III, Madrid, Spain
    9. 9 Fundación de Investigación, La Paz University Hospital Health Research Institute, Madrid, Spain
    10. 10 Foundation for Research and Biomedical Innovation of Primary Care of the Community of Madrid (FIIBAP), Madrid, Spain
    11. 11 Department of Preventive Medicine and Public Health, Universidad Autonoma de Madrid, Madrid, Spain
    12. 12 CIBERESP, Madrid, Spain
    13. 13 IMDEA-Food, CEI UAM+CSIC, Madrid, Spain
    14. 14 Centro de Salud Las Calesas, SERMAS, Madrid, Spain
    15. 15 Medicina Preventiva, Hospital Clinico San Carlos, Madrid, Spain
    1. Correspondence to Dr Miguel Salinero-Fort; miguel.salinero{at}salud.madrid.org

    Abstract

    Objectives To evaluate the external validity of the FINDRISC, DESIR and ADA risk scores for the prediction of diabetes in a Spanish population aged >45 years and to test the possible improvement of FINDRISC by adding a new variable of high risk of depression when Patient Health Questionnaire-9 (PHQ-9) questionnaire score ≥10 (FINDRISC-MOOD).

    Design Prospective population-based cohort study.

    Setting 10 primary healthcare centres in the north of the city of Madrid (Spain).

    Participants A total of 1242 participants without a history of diabetes and with 2-hour oral glucose tolerance test (OGTT) plasma glucose <200 mg/dL (<11.1 mmol/L) were followed up for 7.3 years (median) using their electronic health records (EHRs) and telephone contact.

    Primary and secondary outcome measures Diabetes risk scores (FINDRISC, DESIR, ADA), PHQ-9 questionnaire and 2-hour-OGTT were measured at baseline. Incident diabetes was defined as treatment for diabetes, fasting plasma glucose ≥126 mg/dL (≥7.0 mmol/L), new EHR diagnosis or self-reported diagnosis. External validation was performed according to optimal cut-off, sensitivity, specificity and Youden Index. Comparison between diabetes risk scores, including FINDRISC-MOOD (original FINDRISC score plus five points if PHQ-9 ≥10), was measured by area under the receiver operating characteristic curve (AUROC).

    Results During follow-up, 104 (8.4%; 95% CI, 6.8 to 9.9) participants developed diabetes and 185 had a PHQ-9 score ≥10. The AUROC values were 0.70 (95% CI, 0.67 to 0.72) for FINDRISC-MOOD and 0.68 (95% CI, 0.65 to 0.71) for the original FINDRISC. The AUROCs for DESIR and ADA were 0.66 (95% CI, 0.63 to 0.68) and 0.66 (95% CI, 0.63 to 0.69), respectively. There were no significant differences in AUROC between FINDRISC-MOOD and the other scores.

    Conclusions The results of FINDRISC-MOOD were like those of the other risk scores and do not allow it to be recommended for clinical use.

    • Risk Factors
    • Surveys and Questionnaires
    • General diabetes

    Data availability statement

    Data are available upon reasonable request.

    http://creativecommons.org/licenses/by-nc/4.0/

    This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available upon reasonable request.

    View Full Text

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Footnotes

    • Collaborators SPREDIA-2 Group: Leopoldo Pérez-Isla (Hospital Clínico de San Carlos), Ignacio Vicente (CS Monóvar), Sara Artola (CS Ma Jesús Hereza), Ma Isabel Granados-Menéndez (CS Monóvar), Domingo Beamud-Victoria (CS Felipe II), Isidoro Dujovne-Kohan (CS Los Castillos), Rosa María Chico-Moraleja (Hospital Central de la Defensa), Carmen Martín-Madrazo (CS Monóvar), Juan Cárdenas-Valladolid (Gerencia de Atención Primaria), Rosario Echegoyen de Nicolás (CS Benita de Ávila), Concepción Aguilera Linde (CS Ciudad Periodistas), Álvaro R Aguirre De Carcer Escolano (CS La Ventilla), Patricio Alonso Sacristán (CS Ciudad Periodistas), M Jesús Álvarez Otero (CS Dr Castroviejo), Paloma Arribas Pérez (CS Santa Hortensia), Maria Luisa Asensio Ruiz (CS Fuentelarreina), Pablo Astorga Díaz (CS Barrio Pilar), Begoña Berriatua Ena (CS Dr Castroviejo), Ana Isabel Bezos Varela (CS José Marva), María José Calatrava Triguero (CS Ciudad Jardín), Carlos Casanova García (CS Barrio Pilar), Ángeles Conde Llorente (CS Barrio Pilar), Concepción Díaz Laso (CS Fuentelarreina), Emilia Elviro García (CS Ciudad Periodistas), Orlando Enríquez Dueñas (CS Fuentelarreina), María Isabel Ferrer Zapata (CS El Greco), Froilán Antuña (CS Ciudad Periodistas), Maria Isabel García Lazaro (CS Ciudad Periodistas), Maria Teresa Gómez Rodríguez (CS Barrio Pilar), África Gómez Lucena (CS La Ventilla), Francisco Herrero Hernández (CS La Ventilla), Rosa Julián Viñals (CS Dr Castroviejo), Gerardo López Ruiz Ogarrio “in memoriam” (CS Barrio Pilar), Maria Del Carmen Lumbreras Manzano (CS José Marva), Sonsoles Paloma Luquero López (CS Ciudad Periodistas), Ana Martínez Cabrera Peláez (CS Barrio Pilar), Montserrat Nieto Candenas (CS La Ventilla), María Alejandra Rabanal Carrera (CS Barrio Pilar), Ángel Castellanos Rodríguez (CS Ciudad Periodistas), Ana López Castellanos (CS La Ventilla), Milagros Velázquez García (CS Barrio Pilar) and Margarita Ruiz Pacheco (CS Dr. Castroviejo).

    • Contributors MS-F, CDB-L, PG-C and FJSA-R contributed to conceptualisation, methodology, validation, formal analysis, writing—original draft and visualisation. JMM-P, CL-R, BF-P, EE-D, FG-I and TG-A contributed to investigation and resources. VMC-DR, VS, CS-R and SL-L contributed to supervision and validation. VI-C and BT contributed to review and editing. JC-V contributed to data curation and supervision. FR-A contributed to validation, final review and editing. The SPREDIA-2 group encouraged patient participation and supported patients during follow-up. They also facilitated data collection during the follow-up period. All authors contributed to the article and approved the submitted version.

    • Funding This work was supported by Instituto de Salud Carlos III (ISCIII) and was co-funded by the European Union. Grant numbers PI15/00259, PI18/01025 and PI22/01499.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.